A method for producing nanomaterial product which comprises at least one hybrid nanoparticle Gold-metal-Polymer, the polymer comprising at least one biopolymer, the atoms of metal being linked with the atom of Gold, the metal being chosen among: Gd, Co, Eu, Tb, Ce, Mn, Fe, Zn, Cu, the method being realized in an aqueous solvent, without reactive or stabilizer agent, and presenting a step of reducing: tetrachloroauric acid (HAuCl.sub.4) and metal ions, in the presence of the biopolymer, the biopolymer being used as a stabilizer agent.

A multimodal PET (positron emission tomography)/MRI (magnetic resonance imaging) contrast agent, a process of synthesizing said PET/MRI contrast agent, and a pharmaceutical formulation comprising said PET/MRI contrast agent are disclosed. The PET/MRI contrast agent comprises a magnetic signal generating core, and a coating portion formed at least partially over a surface of said magnetic signal generating core, wherein the coating portion comprises a plurality of layers, including an inner layer having a functionalized surface, and an outer layer in the form of a radionuclide electrolessly plated layer formed on said functionalized surface.

Mesoporous silica nanoparticles (MSNs) that may be useful as ultrasound contrast agents for detecting and treating bladder cancer are described herein. The MSNs include a lanthanide, a fluorophore, and an agent detectable by ultrasound.

The present invention concerns aza-cryptophanes, processes for preparation thereof, and their uses, in particular as in vivo diagnostic tools when complexing a hyperpolarized noble element, or in nanoemulsions.

The present disclosure provides method of making a nanoparticle complex wherein the nanoparticle complex comprises a ligand and a metal cation. The disclosure also provides nanoparticle complexes, methods of treating a disease in a patient utilizing the nanoparticle complexes, methods of identifying a disease in a patient utilizing the nanoparticle complexes, and kits involving the nanoparticle complexes.

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

Provided are proteins/peptides. The proteins or peptides comprise a sequence designed by the methods described herein. The proteins and peptides may have one or more trifluoroleucine (L.sub.TF, which may be referred to as TFL or LTF throughout) residues. The proteins may have or contain the following sequence: VX.sub.1X.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7X.sub.8X.sub.9X.sub.10X.sub.11X.sub.12X.sub.13X.sub.14X.sub.15X.sub.16X.sub.17X.sub.18X.sub.19X.sub.20X.sub.21X.sub.22X.sub.23X.sub.24X.sub.25X.sub.26X.sub.27X.sub.28X.sub.29X.sub.30X.sub.31X.sub.32X.sub.33X.sub.34X.sub.35X.sub.36X.sub.37 (SEQ ID NO:1), where X.sub.1 is A, E, D, R, H, K, Q, N, or S; X.sub.2 is A, E, N, or Q; X.sub.3 is A, V, L, I, Q, M, or L.sub.T; X.sub.4 is A, E, R, D, H, I, L, T, K, Q, N, or L.sub.T; X.sub.5 is A, F, Q, R, K, H, D, S, or E; X.sub.6 is A, L, I, or L.sub.TF; X.sub.7 is A, K, or E; X.sub.8 is A, K, E, D, R, H, Q, or N; X.sub.9 is A, T, I, L, Q, or L.sub.TF; X.sub.10 is A, L, I, or LT; X.sub.11 is A, E, D, H, P, I, L, K, Y, N, Q, R, or LT; X.sub.12 is A, Q, H, E, D, K, R, or N; X.sub.13 is A, M, I, L, Q, T, or L.sub.TF; X.sub.14 is A, L, D, E, K, I, or L.sub.TF; X.sub.15 is A, E, D, H, Y, I, L, R, K, Q, N, or Lu; X.sub.16 is A, E, or Q; X.sub.17 is A, L, M, I, V, or L.sub.TF; X.sub.18 is A, K, E, D, K, R, H, N, or Q; X.sub.19 is A, N, D, K, R, H, Q, or E; X.sub.20 is A, L, T, I, M, R, or L.sub.TF; X.sub.21 is A, N, or Q; X.sub.22 is K, A, E, I, L, M, R, H, D, Q, N, S, or L.sub.TF; X.sub.23 is A, Q, N, I, L, or L.sub.TF; X.sub.24 is A, L, I, M, T, or LT; X.sub.25 is A, H, Q, R, K, D, N, Y, I, E, L, T, or LT; X.sub.26 is A, D, E, R, K, Q, H, N, or T; X.sub.27 is A, V, I, Q, L, T, or L.sub.TF; X.sub.28 is A, R, E, D, K, H, N, Q, or T; X.sub.29 is A, H, E, R, D, K, I, L, N, Q, T, Y, or L.sub.TF; X.sub.30 is L, A, D, K, I, N, Q, or L.sub.TF; X.sub.31 is A, L, Q, I, or L.sub.TF; X.sub.32 is E, D, K, H, N, Q, A, L, R, I, Y, or L.sub.TF; X.sub.33 is A, N, Q, D, E, H, K, R, or S; X.sub.34 is Q, I, L, A, M, or LT; X.sub.35 is S, A, P, or Q; X.sub.36 is A, K, T, D, R, H, N, Q, or E; X.sub.37 is A, L, I, K, D, N, Q, R, or L.sub.TF; where at least one of X.sub.3, X.sub.4, X.sub.6, X.sub.9, X.sub.10, X.sub.11, X.sub.13, X.sub.14, X.sub.15, X.sub.16, X.sub.17, X.sub.20, X.sub.22, X.sub.23, X.sub.24, X.sub.25, X.sub.27, X.sub.29, X.sub.30, X.sub.31, X.sub.32, X.sub.34, X.sub.37 or any L is replaced with L.sub.TF. The proteins and peptides may have desirable self-assembling properties such that they form supramolecular structures (e.g., fibers or fibrils). The supramolecular structures may further gelate water such that a hydrogel is formed. The fibers and/or gels may be used to delive

Provided herein are therapeutic nanoparticles having a diameter of between 10 nm to 30 nm, and containing a polymer coating, and a nucleic acid containing a sequence complementary to a sequence within a micro-RNA identified as having a role in cancer cell metastasis or anti-apoptotic activity in a cancer cell (e.g., miR-10b) or a sequence within an mRNA encoding a pro-apoptotic protein that is covalently linked to the nanoparticle. Also provided are pharmaceutical compositions containing these therapeutic nanoparticles. Also provided herein are methods of decreasing cancer cell invasion or metastasis in a subject having a cancer and methods of treating a metastatic cancer in a lymph node in a subject that require the administration of these therapeutic nanoparticles to a subject.

Protein polymer-gold nanoparticles, compositions comprising protein polymer-gold nanoparticles, and uses of protein polymer-gold nanoparticles. A protein polymer-gold nanoparticle comprises a gold core and a plurality of protein polymer molecules coordinated to the gold core via a poly-histidine tag present on each protein polymer molecule. A protein polymer molecule comprises one or more elastin-like polypeptide domain and a coiled-coil region of Cartilage Oligomeric Matrix Protein domain or a variant thereof. For example, the protein polymer-gold nanoparticles can be used in methods of small molecule delivery to an individual.